不同剂量与方式应用尿激酶溶栓治疗急性肺血栓栓塞症临床观察  

A Clinical Observation of Different Dosage and Application of Urokinase in Treatment of Acute Pulmonary Thromboembolism

作　　者：柯荣[1] 刘艳[1] 

机构地区：[1]湖北省松滋市人民医院,434200

出　　处：《医学理论与实践》2012年第15期1815-1816,1820,共3页The Journal of Medical Theory and Practice

摘　　要：目的:不同剂量与方式应用尿激酶溶栓治疗急性肺血栓栓塞症的疗效与安全性观察。方法:我院2009年4月-2011年12月住院24例急性肺血栓栓塞症患者,随机分组,对照组12例,治疗组12例,对照组采用2h内2万U/kg的尿激酶一次性溶栓,治疗组在对照组基础上加用1万U/kg尿激酶,微泵泵入,持续12h,两组疗效及安全性比较。结果:治疗组总有效率为83.3%,对照组总有效率为66.7%。两组总有效率比较差异有统计学意义P<0.05,安全性比较两组出血风险无明显统计学差异。结论:治疗组用2万U/kg尿激酶2h内静滴后继而加用1万U/kg尿激酶微泵泵入,持续12h溶栓治疗肺血栓栓塞症疗效明显优于对照组,其安全性及出血风险比较无明显差异,该方法值得在基层医院中推广。Objective： On the efficacy and safety of different dosage and application of urokinase in treatment of acute pulmonary thromboembolisrrL Methods： In our hospital from April 2009 to December 2011,24 patients hospitalized with acute pulmonary thromboembolism, randomly,12 cases in the control group, the treatment group of 12 cases. Control group using 2 hours of 20 000 U/kg disposable thrombolysis urokinase in treatment group, plus 10 000U/kg urokinase, micro pump,lasting 12 hours, two groups of comparison of efficacy and safety. Results： The total effective rate of the treatment group （83. 3%）, the total effective rate in control group （66. 7%）. The total effective rate of two groups had significant difference P〈0. 05, safety comparison of treatment group, control group had no significant difference in bleeding risk. Conclusion： The two groups with 20 000U/kg within 2 hours of intravenous urokinase and urokinase com- bined with subsequent 10 000U/kg micro pump, 12 hours continuous thrombolytic therapy for pulmonary thromboem- bolism was significantly superior to the control group, the safety risk of hemorrhage and no obvious differences, this method is worthy of popularization in primary hospital.

关 键 词：急性肺血栓栓塞症 尿激酶溶栓 出血风险 

分 类 号：R563.5[医药卫生—呼吸系统]